A multi-center, open-label, Phase I study of single agent RO5045337 administered orally in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML) in blast phase, or refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SCLL).
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2016
At a glance
- Drugs RG 7112 (Primary)
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia
- Focus Adverse reactions
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 12 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.